Article
Clinical and immunological studies in advanced cancer patients sequentially treated with anti CD3 monoclonal antibody (OKT3) and interleukin-2.
Leukemia & lymphoma - 1 Apr 1996
Borrione P, Montacchini L, Beggiato E, Pileri A, Bianchi A, Massaia M
Abstract excerpt
CD3 engagement has been used as a surrogate for antigen-specific stimulation to trigger T cell effector functions. Exogenous IL-2 has been used to prolong and amplify CD3-induced T cell activation. Previous studies have been shown that CD3 reactivity is increased in cancer patients with preactiva...
Topics
- Antibodies, Monoclonal
- CD3 Complex
- CD4-CD8 Ratio
- Drug Administration Schedule
- Female
- HLA-DR Antigens
- Humans
- Immunotherapy
- Infusions, Intravenous
- Interleukin-2
- Leukocyte Count
- Lymphocyte Activation
- Lymphoma, B-Cell
- Male
- Melanoma
- Middle Aged
- Multiple Myeloma
- Phenotype